Compare Fortinet Inc (FTNT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs TransMedics Group Inc — how do they compare? Fortinet Inc trades at $163.28 (market cap $120.53B), while TransMedics Group Inc trades at $77.75 (market cap $2.61B). The key difference: Fortinet Inc is far larger — about 46.2× TransMedics Group Inc's market cap, and Fortinet Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| FTNT | TMDX | |
|---|---|---|
Market Cap | $120.53B | $2.61B |
Sector | Technology | Technology |
52-Week High | $166.83 | $150.42 |
52-Week Low | $74.39 | $61.99 |
Enterprise Value | $117.73B | $3.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $166.83, up 3.87% today, with a bullish technical signal from moving averages and strong quarterly earnings beats. Revenue grew to $6.80B in 2025, with a net income margin of 27.49%, though valuation ratios like P/E of 63.76 and P/S of 17.5 appear elevated. Recent news highlights AI-driven cybersecurity demand as a growth catalyst, with the company expanding its FortiEndpoint platform for AI security.
The outlook is positive due to robust earnings performance and sector tailwinds, but high valuations and competitive pressures pose risks. Analyst consensus is mixed with 42.65% buy ratings, yet the consensus price target of $123.16 suggests caution relative to the current price, indicating potential overvaluation concerns amid growth optimism.
TransMedics (TMDX) trades at $77.46, up 3.85% on the day, with a bullish technical signal and strong analyst support. The company reported robust profitability with a 27.04% net margin and 45.22% ROE, though recent Q1 2026 earnings missed expectations. Strategic expansion into Europe via the PAD Aviation investment aims to strengthen its organ transplant logistics network, a key competitive advantage. The stock's valuation metrics include a P/E of 17.25 and P/S of 4.7.
The outlook remains positive with a $108.71 consensus price target (40% upside), supported by 9 buy ratings. Key opportunities include market share gains and European expansion, while risks involve margin pressure from investments and competitive threats. Execution on growth initiatives amid decelerating revenue growth will be critical for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
